Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Why Mind Medicine Stock Is Skyrocketing Today

Source The Motley Fool

Mind Medicine (NASDAQ: MNMD) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m. ET and had been up as much as 20.7% on the day earlier in the session.

Mind Medicine's valuation is surging following Robert F. Kennedy Jr.'s approval as health and human services (HHS) secretary in yesterday's Senate vote. Kennedy has previously voiced support for psychedelics as therapeutic treatments.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Mind Medicine stock soars on RFK Jr.'s HHS confirmation

In a 52-to-48 vote yesterday, RJK Jr. was approved as the U.S.'s new HHS secretary. Among President Donald Trump's cabinet nominations, Kennedy's confirmation vote was viewed as one of the more likely to fall through. But he was confirmed for the cabinet role with nearly unanimous Republican support. Sen. Mitch McConnell from Kentucky was the only Republican to vote against Kennedy.

RFK Jr. has previously said that he supports the use of psychedelic drugs as therapeutic treatments in some instances. With the new HHS secretary being a supporter of Mind Medicine's core competency, it's possible that the biotech company will have an easier time bringing its products to the market.

What's next for Mind Medicine?

Political dynamics appear to be shifting in Mind Medicine's favor. The clinical-stage biopharmaceutical company has yet to record any revenue, but it's making progress with testing phases for its core treatments.

On Dec. 16, the company published a press release announcing that its phase 3 study for lysergide D-tartrate (LSD) as a treatment for generalized anxiety disorder was scheduled to kick off in the first half of 2025. Then on Jan. 16, the company announced that the first patient in the clinical test had been dosed. Roughly 250 patients are expected to be tested in the trial, and the results are likely to have a big impact on Mind Medicine's share price.

Should you invest $1,000 in Mind Medicine (MindMed) right now?

Before you buy stock in Mind Medicine (MindMed), consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mind Medicine (MindMed) wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $829,128!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of February 7, 2025

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Oil’s Return to $110 Boosts Fed Hike Expectations, Pressuring Gold for Fourth Day Toward $4,100 On October 21, gold prices continued their adjustment, with gold (XAUUSD) dropping intraday to as low as $4,106, nearing the $4,100 mark and marking its fourth consecutive trading day of

Author TradingKey

13 hours ago

On October 21, gold prices continued their adjustment, with gold (XAUUSD) dropping intraday to as low as $4,106, nearing the $4,100 mark and marking its fourth consecutive trading day of

Housing starts fell to the second-lowest since the pandemic shutdown — with the 10-year at 5.12%, who is left to buy?US housing starts dropped 5.2% to 1.221 million in September, the second-lowest pace since the 2020 pandemic shutdown, and building permits hit a three-and-a-half-year low of 1.400 million. Both figures are worse than they look because July and August were revised up. With the 10-year Treasury at 5.117% — only 19bp below its October 5 peak of 5.311% — and the NAHB builder confidence index at 2012 levels, here are the three numbers, the transmission chain from rates to permits, and the two scenarios into the October 28 FOMC.

Author Irene Q.

15 hours ago

US housing starts dropped 5.2% to 1.221 million in September, the second-lowest pace since the 2020 pandemic shutdown, and building permits hit a three-and-a-half-year low of 1.400 million. Both figures are worse than they look because July and August were revised up. With the 10-year Treasury at 5.117% — only 19bp below its October 5 peak of 5.311% — and the NAHB builder confidence index at 2012 levels, here are the three numbers, the transmission chain from rates to permits, and the two scenarios into the October 28 FOMC.

The Dow gained 500 points and the two AI names that matter fell after hours — Netflix's guide is the tell The Dow closed 529.85 points higher at 52,495.88 (+1.02%) and the VIX fell 6.13% to 17.31, but the two stocks that carry the AI trade moved the other way after Tuesday's close: Netflix slipped to $64.74 (-5.8%) after guiding Q4 EPS of $0.67, below the street, while SpaceX jumped about 8% to near $160 on its first profit as a public company and revenue up 161%. Netflix is now below its 52-week low of $65.08. Here are the numbers, the $65 / $70 levels and the two catalysts that matter this week.

Author Irene Q.

16 hours ago

The Dow closed 529.85 points higher at 52,495.88 (+1.02%) and the VIX fell 6.13% to 17.31, but the two stocks that carry the AI trade moved the other way after Tuesday's close: Netflix slipped to $64.74 (-5.8%) after guiding Q4 EPS of $0.67, below the street, while SpaceX jumped about 8% to near $160 on its first profit as a public company and revenue up 161%. Netflix is now below its 52-week low of $65.08. Here are the numbers, the $65 / $70 levels and the two catalysts that matter this week.

Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 21, 2026 Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 21, 2026. Read on for the details.

Author Mitrade

19 hours ago

Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 21, 2026. Read on for the details.

Australian Dollar trades near monthly high, above 0.7000 as hawkish RBA offsets USD uptick The AUD/USD pair trades with a positive bias for the fourth straight day, holding steady above the 0.7000 psychological mark during the Asian session on Wednesday and flirting with the monthly high it touched the previous day.

Author FXStreet

20 hours ago

The AUD/USD pair trades with a positive bias for the fourth straight day, holding steady above the 0.7000 psychological mark during the Asian session on Wednesday and flirting with the monthly high it touched the previous day.

Popular Symbols